Credenceresearch

The   Pulmonary Arterial Hypertension (PAH) Treatment Market   is poised for steady growth, projected to expand from USD 5,820 million in 2024 to approximately USD 6,926.76 million by 2032, with a CAGR of 2.2% during the forecast period. Pulmonary Arterial Hypertension (PAH) is a rare but serious condition characterized by elevated blood pressure in the pulmonary arteries, leading to increased strain on the heart. Over the years, significant advancements in PAH diagnosis and treatment have driven the growth of the global PAH treatment market. The market is witnessing notable expansion due to factors such as increasing prevalence, advancements in therapeutics, and a surge in awareness initiatives. Browse the full report at  https://www.credenceresearch.com/report/pulmonary-arterial-hypertension-pah-treatment-market Market Overview The global PAH treatment market is projected to grow at a compound annual growth rate (CAGR) of 5.8% between 2023 and 2030, fueled by techn...